ASSOCIATION BETWEEN BRANCHED-CHAIN AMINO ACID LEVELS AND OBESITY STATUS
Bénédicte Allam-Ndoul, Frédéric Guénard, Véronique Garneau, Louis Pérusse, Olivier Barbier and Marie-Claude Vohl
Associations between Branched Chain Amino Acid Levels, Obesity and Cardiometabolic Complications.
Bénédicte Allam-Ndoul 1,2, Frédéric Guénard 1,2, Véronique Garneau 1,2, Olivier
Barbier 3, Louis Pérusse 1,4, Marie-Claude Vohl 1,2
¹Institute of Nutrition and Functional Foods, Laval University, Quebec, Canada
2School of Nutrition, Laval University, Quebec, Canada
3Laboratory of Molecular Pharmacology, Endocrinology and Nephrology Axis, CHU
de Quebec Research Center, and Faculty of Pharmacy, Laval University, Quebec, Canada
4Department of Kinesiology, Laval University, Quebec, Canada
* Author to whom correspondence should be addressed:
Marie-Claude Vohl, Ph.D.
Institute of Nutrition and Functional Foods (INAF) Laval University
2440 Hochelaga Blvd Quebec, Quebec Canada, G1V 0A6
Email: marie-claude.vohl@fsaa.ulaval.ca Phone number: (418) 656-2131 ext. 4676
ABSTRACT:
Aim/hypothesis: Leucine, isoleucine and valine are branched chain amino acids
(BCAA). BCAAs are among the 9 essential amino acids and are associated with beneficial health effects. However, previous studies have reported strong associations between increased BCAA levels, obesity and metabolic diseases such as type 2 diabetes. The objective of this study is to investigate the association between plasma BCAA levels, cardiometabolic risk factors and Metabolic Syndrome (MetS) in normal versus overweight/obese subjects. Methods: Mass spectrometry-based metabolite profiling of 200 samples using the Absolute ID p180 Kit was used to compare plasma BCAA levels between overweight/obese subjects with or without MetS and normal weight subjects without MetS. Results: Overweight/obese participants irrespective of their MetS status have higher plasma BCAA levels than normal weight participants (P<0.0001). Obesity-associated MetS appears to worsen the difference with normal weight subjects. Leucine (P=0.005) and isoleucine (P=0.02) levels are correlated with HOMA-IR among obese individuals without MetS. Among obese subjects with MetS leucine levels (P=0.04) are correlated to HOMA-IR whereas leucine and isoleucine are correlated with plasma glucose levels.
Conclusions/interpretation: BCAAs are associated with obesity and MetS. Also,
these results suggest that analyzing BCAAs separately may help for a better understanding of the association between BCAAs obesity and MetS.
Keywords: Leucine, isoleucine, valine, obesity, metabolic syndrome, insulin
RÉSUMÉ :
Contexte : La leucine, l’isoleucine et la valine sont les acides aminés à chaine
ramifiées (AACR). Les AACR font partis des 9 acides aminés essentiels. Ils sont essentiels car ils ne peuvent pas être synthétisés par le corps humain et doivent être fourni par l’alimentation. Bien qu’étant bénéfiques pour la santé, des études ont rapporté une association entre la concentration en AACR, l’obésité et des maladies métaboliques telles que le diabète de type 2. Chez les participants de poids normal ainsi que chez les participants en surpoids/obèses (Ov/Ob), nous avons étudié l’association entre les niveaux plasmatiques en AACR, les facteurs de risque cardiométabolique et le syndrome métabolique (SMet). Méthodes : L’analyse de la composition en AACR de 200 échantillons de plasma d’individus de poids normal et d’individus Ov/Ob avec ou sans SMet a été réalisée par spectrométrie de masse (kit “Absolute ID p180 (Biocrates Life Sciences AG, Austria)). Résultats : Les participants Ov/Ob indépendamment de leurs statut en SMet ont une concentration en AACR plus élevée que les individus de poids normal (p<0.0001). Cette concentration est plus importante chez les individus avec le SMet. Les concentrations en leucine (P=0.005) et en isoleucine (P=0,02) sont corrélées avec le HOMA-IR chez les individus Ov/Ob sans SMet. Chez les individus Ov/Ob avec le SMet, la concentration en leucine (P=0,004) est corrélée à l’indice HOMA-IR alors que la leucine et l’isoleucine sont corrélées au taux de glucose. Conclusion : Les AACR sont associés à l’obésité et au SMet. Ces résultats suggèrent également que l’analyse séparée des AACR pourrait aider à mieux comprendre l’association entre les AACR, l’obésité et le SMet.
1. INTRODUCTION
In recent years, the prevalence of metabolic syndrome (MetS) paralleled the increase in the prevalence of obesity.The MetS is characterized by the clustering of abdominal obesity, dyslipidemia, insulin resistance (IR) and hypertension [142]. These conditions are associated with chronic diseases including cardiovascular disease (CVD), type 2 diabetes (T2DM) and hypertension [185;186]. Several studies reported differences in plasma metabolite composition between obese and non-obese individuals. Specific metabolite signatures including amino acids, acylcarnitines or glycerophospholipids have been associated with obesity [155;168].
Leucine, isoleucine and valine are collectively referred as BCAAs due to their shared structural features in side-chain and a common catabolic pathway [187]. They are 3 of the 9 essential amino acids and are abundant in the diet representing up to 15-25% of total protein intake [173]. BCAA-rich diets are often associated with beneficial health effects [188;189]. Isoleucine has hypoglycemic effects in muscles and plays a role in the depression of gluconeogenesis rat liver [173]. BCAAs also promote protein synthesis, cellular metabolism and cell growth [190;191]. However, despite these effects on metabolic health, several studies have indicated that increased FAsting levels of circulating BCAAs are associated with poor metabolic health. For instance, Yang et al. showed a positive and significant association between plasma BCAA levels and CVD risk factors [192]. Newgard et al. reported that increased BCAA levels are associated with high risk of T2DM and IR in humans and animals [155].
Therefore, the aim of the present study was to investigate the relationship between plasma BCAA levels, obesity and MetS status.
2. METHODS
Subjects
Men (n=101) and women (n=99) enrolled in the present study were aged between 18 and 55 years as previously described [152]. This study was divided into two recruitment phases: from May 2004 to December 2004 and from March 2006 to April 2007. Participants were recruited in the Quebec City metropolitan area using advertisements in local newspapers, radio stations, and electronic group messages sent to university and hospital employees. A socio-demographic questionnaire including questions on lifestyle habits was filled by all participants during a visit. All subjects gave their written consent to participate in the study, which has been approved by the ethics committee of Laval University.
Clinical and anthropometric measurements
BMI (kg/m2) was calculated by dividing the weight (kg) by squared height(m2). The
overweight/obese group had a BMI≥ 25 kg/m2 and the normal weight group had a
BMI<25 kg/m2. Resting blood pressure measurements were performed after a 5
minutes rest in a sitting position. Phase I and V of Korotkoff sounds being respectively used for systolic blood pressure (SBP) and diastolic blood pressure (DBP).
Individuals with MetS had at least 3 of the following five criteria: waist circumference (WC) > 88 cm for women and 102 cm for men, FAsting plasma triglycerides (TG) ³1.7 mmol/L, high-density lipoprotein cholesterol (HDL-C) levels £ 1.03 mmol/L for men and 1.29 mmol/L for women, glucose levels ³ 5.6 mmol/L and resting blood pressure ³ 130/85 mmHg.
Lipid profile
Blood glucose was measured after a 12h FAst. FAsting blood samples were obtained from an antecubital vein into vacutainer tubes containing EDTA. Using the Olympus AU400e system (Plympus America Inc., Melville, N.Y., USA) total cholesterol (Total-C) and TG levels were determined from plasma and lipoprotein fractions. A precipitation of low-density lipoprotein (LDL) fraction in the infranatant with heparin-manganese chloride [153] was used to obtain the HDL-C fraction. LDL-C concentrations were estimated using Friedewald’s equation [193].
Metabolite profiling
FAsting plasma samples were obtained from 200 participants. BCAA profiling of these samples were achieved using the Absolute ID p180 Kit for mass spectrometry (Biocrates Life Sciences AG, Austria). Assay used 10 µL of plasma from each subject. The concentrations of all BCAAs were reported in µM.
Statistical analyses
Transformations were applied to the variables that were not normally distributed. Logarithmic transformations were performed for FAsting insulin, total-C and HDL-C and an inverse transformation for TG and FAsting glucose. All analyses were adjusted for age and sex except for WC which was also adjusted for BMI. Analysis of variance was used to underline the differences in metabolic characteristics between obese/overweight and normal-weight participants with or without MetS. The significance level of all analyses was set at p≤ 0.05. The results are presented for each BCAA and for the combination of all BCAAs (leucine, isoleucine and valine). To detect correlations between each BCAA or total BCAA levels and CVD disease risk factors (WC, total-C, TG, HDL-C, LDL-C, glucose, insulin, SBP, DBP and HOMA-IR), partial Pearson correlations were used for the 3 groups (overweight/obese/+MetS, overweight/obese/-MetS, normal weight/-MetS). HOMA- IR was calculated using the following formula [FAsting glucose (mmol/L)]*[insulin (mU/L)]/22.5 [194]. All statistical analyses were performed using SAS statistical software version 9.2 (SAS Institute, Inc, Cary, NC, USA).
3. RESULTS
Metabolic characteristics of the population
Descriptive characteristics of study participants are presented in Table 1. Groups were defined according to BMI and MetS status. Overweight/obese individuals with or without MetS were older than normal weight subjects. Among obese individuals, subjects with MetS were older than those without MetS. As expected, WC and fat mass increased progressively from normal weight to overweight/obese participants. The same trend was observed for FAsting insulin and for SBP. The overweight/obese subjects with MetS had a more deteriorated plasma lipid profile including increased plasma TG levels and decreased plasma HDL-C levels compared to overweight/obese without MetS or normal weight individuals. These differences remained significant after further adjustment for the confounding effect of age. There was no significant difference between groups for plasma LDL-C levels. Normal weight individuals had a lower HOMA-IR (1.61±0.94) than overweight/obese with (5.33±3.69) or without (2.98±2.64) MetS.
BCAA plasma levels
Globally, participants had higher plasma levels of valine (262.2±56.3 µM) than leucine (163.3±30.8 µM) and isoleucine (82.1±15.6 µM; Table 2). Overweight/obese individuals with MetS had higher levels of each BCAA than overweight/obese without MetS or than normal weight individuals. When analysing the combination of all BCAAs, the same trend was observed, overweight/obese group with MetS had the highest levels (507.7±93.3 µM), overweight/obese participants without MetS had intermediate levels (460.8±83.4 µM) and normal weight individuals had the lowest levels (413.8±83.5 µM).
Relation between cardiometabolic risk factors and BCAAs
The correlation coefficients between each BCAA and CVD risk factors were computed. There was a positive correlation between WC and leucine among overweight/obese participants without MetS (r=0.37; p=0.0008) (Table 3). No association was found for overweight/obese with MetS and normal weight individuals. There was also a positive correlation between HOMA-IR index and leucine among overweight/obese subjects without MetS (r=0.022; p=0.05). This correlation was not seen among overweight/obese with MetS and normal weight subjects. Finally, correlations between FAsting glucose and leucine levels (r=0.36; p=0.02) were observed only among overweight/obese subjects with MetS.
For isoleucine, there was a positive correlation with WC for overweight/obese groups with (r=0.34; p=0.02) and without MetS (r=0.31; p=0.004). Isoleucine was correlated to FAsting glucose levels among overweight/obese participants with MetS (r=0.35; p=0.02). For HOMA-IR index a positive correlation with isoleucine was seen among overweight/obese participants with (r=0.31; p=0.04) or without (r=0.25; p=0.02) MetS. No significant correlation was observed among normal weight individuals.
Regarding valine, results showed that there was only one significant correlation. Among overweight/obese participants, valine was correlated with WC (r=0.29; p=0.009). Finally, there was a positive correlation between total BCAAs and WC among overweight/obese individuals without MetS (r=0.35; p=0.002). An association between total BCAAs and HOMA-IR index among overweight/obese subjects without MetS (r=0.21; p=0.05) was also observed.
4. DISCUSSION
BCAAs are essential amino acids. Although their beneficial effects on health have been proven, it seems that increased plasma BCAA levels are associated with several metabolic conditions such as obesity, MetS, IR and T2DM [155;179;195]. The aim of this study was to investigate the association between plasma BCAA levels, obesity and MetS status.
Abdominal obesity is one of the MetS feature. However, all obese individuals do not have MetS [196;197]. Knowing this, it is interesting to see to what extent BCAA levels are associated with obesity and MetS status. The correlation of all three BCAAs with different CVD risk factors among overweight/obese with or without MetS and normal weight individuals has been investigated. It has been known for some time that obesity is accompanied with changes in circulating levels of BCAAs [198;199].
In a study on rodents, She et al. showed that BCAA serum concentrations were significantly higher among obese rodents than among lean ones [200]. In a human trial, Lackey et al. detected an increase of BCAA concentrations among obese subjects in comparison to lean individuals [201]. In the present study, significant correlations between WC and isoleucine were seen among overweight/obese subjects with and without MetS, the same association was only observed among overweight/obese subjects without MetS as far as leucine, valine and total BCAAs levels are concerned. BCAA levels were higher among overweight/obese with MetS than without MetS. In the present study, an increase of leucine, isoleucine and valine was observed among overweight/obese individuals compared to normal weight individuals. When MetS status is considered, overweight/obese individuals with MetS have a higher amount of each BCAA compared to overweight/obese participants without MetS. In a study by Serralde-Zuniga et al., there was an increase in serum BCAA concentrations among subjects with MetS relative to subjects without MetS [202]. This shows that overweight/obese subjects have a higher amount of circulating BCAAs than lean individuals and that MetS is associated with a further increase of BCAA levels. In the present study, the same
phenomenon is observed. Moreover, when analysing each BCAA independently in association with WC, it seems that isoleucine is associated with obesity irrespectively of the MetS status whereas valine and leucine are associated with obesity but not with MetS status.
There was a positive and significant association of isoleucine levels and HOMA-IR among overweight/obese individuals irrespective of MetS status. No association was seen for normal weight participants. Leucine and the combination of the 3 BCAAs were correlated to HOMA-IR but only among overweight/obese subjects without MetS. For valine levels, there was no association with HOMA-IR. IR is a physiological condition in which cells fail to respond to the normal action of insulin [42]. The body produces insulin to maintain glucose levels, but cells become resistant to insulin and are unable to use it as effectively [203]. Beta cells in the pancreas subsequently increase their production of insulin, further contributing to increased insulin levels [203]. IR is a common feature of obesity and an important risk factor for the development of T2DM, MetS and CVD [204]. Studies on BCAA supplementation in obese and normal weight animals and humans indicated that circulating amino acids may directly promote IR [155;205]. In fact, in obese and IR individuals, an increase of plasma BCAA levels is often observed [206]. More interestingly, weight loss among obese subjects triggers an intense decline in circulating BCAA levels [207], and improves insulin sensitivity [208;209]. In the current study, when analysing different groups, even though HOMA-IR index was higher among overweight/obese people with MetS, overweight/obese participants without MetS can also be considered as being IR. When analysing the effect of each BCAA, isoleucine seems to be correlated to HOMA-IR among overweight/obeseirrespective of MetS status. On the other hand, the association of leucine with HOMA-IR is only significant among overweight/obese without MetS. An increase of HOMA-IR, along with an increase of each BCAA plasma levels among overweight/obese people was observed in the present study. It is well documented that the increase of BCAA levels in obese/overweight individuals is associated with a degradation of insulin sensitivity [155;171]. The present study
shows that leucine and isoleucine but not valine seems to be linked to IR among overweight/obese individuals without MetS. When MetS is taken into account, this association remains significant only for isoleucine. With further analyses these two BCAAs could be used as markers of early (leucine) and later (isoleucine) stages of IR and also as a predictor of MetS in obese people (isoleucine). Monitoring changes in leucine and isoleucine circulating levels may provide insights into the initiation of metabolic diseases such as T2DM. Metabolic diseases are often present several years before becoming clinically apparent. For example, by the time relative insulin deficiency manifests itself as hyperglycemia and T2DM diagnosis is made, significant pancreatic alpha-cell insufficiency has already occurred [210]. Clinical predictors such as BMI or blood glucose levels can help for the prediction of T2DM. Unfortunately, they are often used when the disease is at an advanced stage [211]. A study in young Finnish adults by Wurtz et al. demonstrated on one hand that the metabolic signature of IR was modulated by obesity and on the other hand that plasma BCAA levels could be used as markers of early stage of IR because the metabolic profile of the participants was not deteriorated enough [212]. Finally, a study led among children and adolescent suggested that changes in BCAA levels might be an early manifestation of metabolic disorders coming with overeating [213]. This really underlines the fact that plasma BCAA circulating levels can predict the future development of metabolic diseases.
There was a correlation between leucine, isoleucine and FAsting glucose levels but only among obese/overweight individuals with MetS. It seems that when we consider total BCAAs this association is no longer significant. In this study, increased FAsting glucose levels were seen with obesity. Obese/overweight subjects had a higher blood glucose levels than normal weight individuals, and MetS increased this level. However the obese/overweight participants with MetS had impaired FAsting glucose (>5.6 mmol/L). This may be an explanation why no association was observed between BCAAs and plasma glucose levels in obese/overweight group without MetS. Indeed, their metabolic status is probably
not deteriorated enough to alter or affect FAsting glucose levels. This suggests that plasma BCAA concentrations might serve as a better indicator of impaired IR in pre-diabetic state than plasma glucose levels.
In conclusion, results of the present study suggest that plasma BCAA levels could be used as a predictor for future metabolic diseases among obese/overweight people. However, to confirm this hypothesis, a longitudinal study must be performed. It is also important to separate the action of each BCAA because they do not seem to be all associated to the same extent with cardiometabolic risk factors.
ACKNOWLEDGEMENTS
This research would not have been possible without the excellent collaboration of all the participants. We would like to thank Marie-Eve Bouchard, Steve Amireault, Diane Drolet, and Dominique Beaulieu for their involvement in the recruitment of the subjects, study coordination, and data collection and Véronique Garneau for the statistical analyses. We would also like to thank Chenomx Inc. (Edmonton, Canada) who performed the mass spectrometry analyses to obtain plasma BCAA levels.
FUNDING
This study was supported by a grant from the Canadian Institutes of Health Research (CIHR). M.C.V. holds a Tier 1 Canada Research Chair in Genomics Applied to Nutrition and Health.
CONTRIBUTION STATEMENT
LP and MCV contributed to the conception and design of this study. BAN and VG participated to statistical analyses BAN, VG, FG, OB, LP and MVC participated to the interpretation of data. BAN and FG drafted the manuscript. VG, OB and LP critically revised the article for intellectual content. All authors approved the final manuscript. ANB and VG are responsible for the integrity of the work as whole.
Table 1 Baseline characteristics of study participants MetS- MetS+ NW Ov/Ob Ov/Ob P- valuex (n=65) (n=83) (n=46) Age(years)d 28.9±7.4a 35.7±10.4b 37.9±10.0c <0.0001 BMI (Kg/m²) d 22.2±1.8 a 31.4±4.2 b 34.3±4.9 c <0.0001 Waist circumference (cm) e 74.7±5.7 a 97.8±10.8 b 109.0±11.9 c <0.0001 Fat mass (kg)d 14.54±4.25 a 31.30±9.01 b 36.52±10.46 c <0.0001 Lean mass (kg)d 48.93±8.94 a 57.47±11.11b 65.33±12.13c <0.0001
Systolic blood pressure (mmHg)d 115.9±9.8 a 119.9±9.0 b 130.1±10.6 c <0.0001
Diastolic blood pressure (mmHg)d 74.0±9.9 a 77.7±7.7a 83.5±9.5b <0.0001 Fasting glucose (mmol/L)d, g 5.8±1.3 a 5.4±0.5 b 6.1±1.1 c 0.002
Fasting insulin (ρmol/L)d,f 48.7±17.1 a 86.1±56.3 b 133.1±72.3 c <0.0001 HOMA-IR d,f 1.84±0.94 a 2.98±1.77 b 5.33±3.70 c <0.0001